This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ginsburg, A. S.
Right arrow Articles by Grosset, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ginsburg, A. S.
Right arrow Articles by Grosset, J. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2005, p. 3977-3979, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3977-3979.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Emergence of Fluoroquinolone Resistance in Mycobacterium tuberculosis during Continuously Dosed Moxifloxacin Monotherapy in a Mouse Model

Amy Sarah Ginsburg,1 Ronggai Sun,2 Heather Calamita,3 Cherise P. Scott,1 William R. Bishai,1 and Jacques H. Grosset1*

Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland,1 AERAS Global TB Vaccine Foundation, Bethesda, Maryland,2 United States Patent and Trademark Office, Washington, D.C.3

Received 3 June 2005/ Returned for modification 4 June 2005/ Accepted 9 June 2005

Fluoroquinolone resistance in tuberculosis may rapidly emerge. Mice infected with high titers of aerosolized Mycobacterium tuberculosis and treated for 8 weeks with four concentrations of moxifloxacin (0.125, 0.25, 0.50, and 1.0%) mixed into the diet had drug concentrations of 2.4, 4.1, 5.3, and 17.9 µg/ml, respectively, in blood. Selection of fluoroquinolone-resistant mutants occurred in all surviving mice.

* Corresponding author. Mailing address: Center for Tuberculosis Research, 1503 E. Jefferson Street, Baltimore, MD 21231-1001. Phone: (410) 955-3507. Fax: (410) 614-8173. E-mail: jgrosse4{at}jhmi.edu.

Antimicrobial Agents and Chemotherapy, September 2005, p. 3977-3979, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3977-3979.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ferran, A. A., Kesteman, A.-S., Toutain, P.-L., Bousquet-Melou, A. (2009). Pharmacokinetic/Pharmacodynamic Analysis of the Influence of Inoculum Size on the Selection of Resistance in Escherichia coli by a Quinolone in a Mouse Thigh Bacterial Infection Model. Antimicrob. Agents Chemother. 53: 3384-3390 [Abstract] [Full Text]  
  • Almeida, D., Nuermberger, E., Tyagi, S., Bishai, W. R., Grosset, J. (2007). In Vivo Validation of the Mutant Selection Window Hypothesis with Moxifloxacin in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother. 51: 4261-4266 [Abstract] [Full Text]  
  • Shi, R., Zhang, J., Li, C., Kazumi, Y., Sugawara, I. (2006). Emergence of Ofloxacin Resistance in Mycobacterium tuberculosis Clinical Isolates from China as Determined by gyrA Mutation Analysis Using Denaturing High-Pressure Liquid Chromatography and DNA Sequencing. J. Clin. Microbiol. 44: 4566-4568 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»